---
figid: PMC6468754__cancers-11-00316-g002
figlink: /pmc/articles/PMC6468754/figure/cancers-11-00316-f002/
number: F2
caption: Vascular endothelial growth factor (VEGF) binds to the VEGF receptor, a receptor
  tyrosine kinase, leading to receptor dimerization and subsequent auto phosphorylation
  of the receptor complex. The phosphorylated receptor then interacts with a variety
  of cytoplasmic signaling molecules, leading to signal transduction and eventually
  angiogenesis. Examples of clinical drugs () that inhibit the pathway are shown.
  PI3K, phosphoinositide-3-kinase; AKT, protein kinase B; mTOR, mechanistic target
  of rapamycin; MEK, MAPK/ERK kinase; ERK, extracellular signal-regulated kinase.
pmcid: PMC6468754
papertitle: Tumor Neovascularization and Developments in Therapeutics.
reftext: Yuki Katayama, et al. Cancers (Basel). 2019 Mar;11(3):316.
pmc_ranked_result_index: '108693'
pathway_score: 0.9526137
filename: cancers-11-00316-g002.jpg
figtitle: Vascular endothelial growth factor (VEGF) binds to the VEGF receptor, a
  receptor tyrosine kinase, leading to receptor dimerization and subsequent auto phosphorylation
  of the receptor complex
year: '2019'
organisms: Homo sapiens
ndex: 1429d542-dea4-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6468754__cancers-11-00316-g002.html
  '@type': Dataset
  description: Vascular endothelial growth factor (VEGF) binds to the VEGF receptor,
    a receptor tyrosine kinase, leading to receptor dimerization and subsequent auto
    phosphorylation of the receptor complex. The phosphorylated receptor then interacts
    with a variety of cytoplasmic signaling molecules, leading to signal transduction
    and eventually angiogenesis. Examples of clinical drugs () that inhibit the pathway
    are shown. PI3K, phosphoinositide-3-kinase; AKT, protein kinase B; mTOR, mechanistic
    target of rapamycin; MEK, MAPK/ERK kinase; ERK, extracellular signal-regulated
    kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - AKT3
  - BRAF
  - HRAS
  - VEGFC
  - AKT1
  - AKT2
  - KDR
  - MTOR
  - ARAF
  - VEGFD
  - PGF
  - KRAS
  - NRAS
  - FLT1
  - FLT4
  - VEGFA
  - VEGFB
  - MAPK1
  - MAPK3
  - MAP2K2
  - MAP2K1
  - Sunitinib
  - Sorafenib
  - Axitinib
  - Pazopanib
  - Vandetanib
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals:
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Axitinib
  source: MESH
  identifier: C503983
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Vandetanib
  source: MESH
  identifier: C452423
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6468754__F2
redirect_from: /figures/PMC6468754__F2
figtype: Figure
---
